


Name	Jeong Uk Lim	
Country	Republic of Korea	
Organization	Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea	
Current Position	Assistant Professor	

Educational Background

2004.03-2010.02 Bachelor's degree, College of Medicine, The Catholic University of Korea,
Republic of Korea

2014.09-2022.03 Doctor's degree, College of Medicine, The Catholic University of Korea,
Republic of Korea

Professional Experiences

2015.03-2016.02 Clinical Fellow of Pulmonology, St.Paul's Hospital, College of Medicine, The Catholic University of Korea, **Republic of Korea**

2016.04-2017.04 Department of Medicine, The Armed Forces Goyang Hospital

2017.04-2019.04 Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Armed Forces Capital Hospital, Seongnam, Korea

2019.05-2020.02.29 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

2020.03.01-Present Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Professional Organizations

2010 The Korean Medical Association

2011 The Korean Association of Internal Medicine

2015 The Korean Academy of Tuberculosis and Respiratory Diseases

2015 The Korean Society of Critical Care Medicine

2021-2023 Member of Editorial Board of Journal of Thoracic Disease

2021 Member of Editorial Board of Tuberculosis and Respiratory Diseases

2023 Member of Editorial Board of BMC Pulmonary Medicine

2023 Member of Editorial Board of Frontiers in Oncology

Main Scientific Publications

1. Lim JU, Lee E, Lee SY, Cho HJ, Ahn DH, Hwang Y, et al. Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. *Transl Lung Cancer Res.* 2023;12(4):857-76.
2. Kim S, Lim JU, Kang HS, Shin AY, Yeo CD, Kim SK, et al. The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential biomarker. *Transl Lung Cancer Res.* 2023;12(1):79-95.
3. Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, et al. Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. *Cancer Res Treat.* 2023;55(1):103-11.
4. Hong YJ, Han S, Lim JU, Kang HS, Kim SK, Kim JW, et al. Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients With Lung Cancer. *Clin Lung Cancer.* 2023;24(5):459-66.
5. An TJ, Kim JH, Hur J, Park CK, Lim JU, Kim S, et al. Tiotropium Bromide Improves Neutrophilic Asthma by Recovering Histone Deacetylase 2 Activity. *J Korean Med Sci.* 2023;38(12):e91.
6. Min JW, Lim JU. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use. *Semin Oncol.* 2022;49(2):141-7.
7. Lim JU, Yoon HK. Narrative review: association between lung cancer development and ambient particulate matter in never-smokers. *J Thorac Dis.* 2022;14(2):553-63.
8. Lim JU, Yeo CD. Update on adjuvant therapy in completely resected NSCLC patients. *Thorac Cancer.* 2022;13(3):277-83.
9. Lim JU, Kang HS, Shin AY, Yeo CD, Park CK, Lee SH, et al. Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis. *Thorac Cancer.* 2022;13(9):1349-60.
10. Lim JU, Kang HS, Shin AY, Yeo CD, Kim SK, Kim JW, et al. Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment. *Thorac Cancer.* 2022;13(23):3384-92.

11. Kim S, Lim JU. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management. *J Thorac Dis.* 2022;14(5):1684-95.
12. Jo YS, Rhee CK, Yoon HK, Park CK, Lim JU, An TJ, et al. Evaluation of asthma-chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease. *J Inflamm (Lond).* 2022;19(1):25.
13. Lim JU, Yoon HK. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. *Cytokine.* 2021;138:155363.
14. Lim JU, Lee JS, Lee JH, Lee SD, Oh YM, Rhee CK. Clinical impact of long-term change in air trapping on pulmonary function and computed tomography parameters in chronic obstructive pulmonary disease. *Korean J Intern Med.* 2021;36(3):636-46.
15. Lim JU, Kim SH, Kang HS, Kim SK, Kim JS, Kim JW, et al. Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy. *J Clin Med.* 2021;10(16).
16. Lim JU, Kang HS, Yeo CD, Kim JS, Park CK, Kim JW, et al. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. *J Thorac Dis.* 2021;13(5):2824-32.
17. Lim JU, Kang HS. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer. *Ann Transl Med.* 2021;9(9):809.
18. Lim JU, Kang HS. Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer. *Transl Lung Cancer Res.* 2021;10(9):3709-12.
19. Lim JU. Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors. *Clin Lung Cancer.* 2021;22(5):e786-e92.
20. Lim JU, Oh J, Kim HW, Ban WH, Park ES, Ha JH, et al. Factors associated with discrepancy between fresh frozen and permanent biopsy from medical thoracoscopy: single center analysis of 172 medical flexible thoracoscopy cases. *J Thorac Dis.* 2020;12(12):7164-73.
21. Lim JU, Kang HS, Yeo CD, Kim JS, Park CK, Kim YH, et al. Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study. *Int J Chron Obstruct Pulmon Dis.* 2020;15:3323-34.
22. Lim JU, Han S, Kim HC, Choi CM, Jung CY, Cho DG, et al. Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. *J Thorac Dis.* 2020;12(9):4612-22.
23. Choi JY, Lim JU, Jeong HJ, Lee JE, Rhee CK. Association between peripheral blood/bronchoalveolar lavage eosinophilia and significant oxygen requirements in patients with acute

eosinophilic pneumonia. *BMC Pulm Med.* 2020;20(1):22.

24. Lim JU, Yeo CD, Rhee CK, Kang HS, Park CK, Kim JS, et al. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. *Int J Chron Obstruct Pulmon Dis.* 2019;14:929-38.

25. Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, et al. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. *Sci Rep.* 2019;9(1):4721.

26. Lim JU, Park CK, Kim TH, Jang AS, Park YB, Rhee CK, et al. The Difficulty Of Improving Quality Of Life In COPD Patients With Depression And Associated Factors. *Int J Chron Obstruct Pulmon Dis.* 2019;14:2331-41.

27. Lim JU, Kim EK, Lim SY, Lee JH, Lee JS, Lee SD, et al. Mixed Phenotype of Emphysema and Airway Wall Thickening Is Associated with Frequent Exacerbation in Chronic Obstructive Pulmonary Disease Patients. *Int J Chron Obstruct Pulmon Dis.* 2019;14:3035-42.

28. Lim JU, Hong SW, Ko JH. Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials. *Ther Adv Respir Dis.* 2019;13:1753466619875930.

29. Lim JU, Gil BM, Kang HS, Oh J, Kim YH, Kwon SS. Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis. *BMC Pulm Med.* 2019;19(1):120.
